Catheter Introducer Sheaths Market Size & Share 2026-2035

Catheter Introducer Sheaths Market Size

The catheter introducer sheaths market is estimated at USD 1.3 billion in 2025 and USD 1.4 billion in 2026, with revenue projected to reach USD 2.5 billion by 2035 at a 6.7% CAGR.

Catheter introducers provide the controlled percutaneous channel through which diagnostic and therapeutic catheters enter a vessel or body cavity. In the United States, these devices are regulated as Class II catheter introducers under 21 CFR 870.1340 and generally require a 510(k) premarket notification before commercialization ^{[1]U.S. Code of Federal Regulations, 21 CFR 870.1340 Catheter Introducer, Classification, govregs.com}. That pathway has supported iterative design changes in coatings, wall thickness, hemostasis valves, and steerability, although each modification still requires performance and biocompatibility evidence.

Underlying procedure demand remains tied to cardiovascular and neurovascular disease. Cardiovascular diseases caused an estimated 19.8 million deaths in 2022, or roughly 32% of global mortality, with heart attack and stroke responsible for 85% of those deaths ^{[2]World Health Organization, Cardiovascular diseases (CVDs), 2024, who.int}. The demand effect is direct: coronary angiography, PCI, electrophysiology procedures, transcatheter valve interventions, and neurovascular thrombectomy each require vascular access. The continued shift from open valve surgery toward transcatheter intervention has strengthened demand for larger-bore and feature-intensive access systems; transcatheter valve procedures expanded at a 12.8% CAGR between 2015 and 2024 while conventional surgical valve procedures contracted .

Integrated designs lead the product mix because they combine the sheath, dilator, valve, and often a side port into a single procedural system. Cardiovascular procedures remain the largest application, while neurovascular demand is supported by the expanding use of mechanical thrombectomy for large-vessel stroke . Hospitals held 62.3% of market revenue in 2025, but ambulatory surgical centers (ASCs) are becoming a more consequential buying channel as elective cardiac procedures move into outpatient settings.

North America accounted for 32.8% of global revenue in 2025. Its installed catheterization-laboratory base, reimbursement infrastructure, and ASC expansion sustain market value despite comparatively moderate procedural growth. Asia Pacific is projected to record the fastest regional CAGR, at 9.1% from 2026 to 2035, as cardiovascular burden is translated into additional interventional capacity in China and India. Abbott, BD, Medtronic, Stryker, and Terumo together represent approximately 42% of global revenue.

This creates two commercially distinct markets within the same category. Standard 5Fr and 6Fr radial products face procurement-led standardization and price comparison, whereas specialty sheaths are selected around access performance, device compatibility, hemostasis control, and clinical workflow. The highest-value opportunities therefore depend less on broad procedure counts than on a manufacturer's ability to align a sheath platform with structural heart, electrophysiology, thrombectomy, or outpatient cath-lab workflows.

Key Drivers

Increasing prevalence of cardiovascular and neurovascular diseases

Cardiovascular disease creates the category's durable procedure base. Ischemic heart disease caused 9.1 million deaths in 2021 and remained the world's leading cause of death ^{[3]World Health Organization, The top 10 causes of death, who.int}. In Asia, cardiovascular disease causes approximately 10.8 million deaths annually, with aging, hypertension, and urbanization increasing the burden on interventional-care systems ^{[4]BMC Cardiovascular Disorders, The burden of cardiovascular disease in Asia from 2025 to 2050, pmc.ncbi.nlm.nih.gov}. China alone has an estimated one in five adults living with cardiovascular disease .

Stroke adds a high-value access demand stream. Global stroke incidence was estimated at 11.81 million new cases in 2021 and is projected to reach 21.43 million by 2050, while prevalence is expected to rise from 93.18 million to 159.31 million . Mechanical thrombectomy requires long, high-performance access systems that accommodate balloon-guide catheters and retrieval devices. U.S. thrombectomy volume was estimated at 39,164 procedures in 2021, with projected annual growth of 5% to 10% as comprehensive stroke networks expand . This differs from routine coronary demand because each newly capable stroke center creates recurring demand for dedicated neurovascular access devices rather than a simple substitution of one sheath type for another.

Technological advancements in catheter introducer sheaths

Product innovation is concentrated in wall geometry, coating durability, hemostasis control, and steering. Hydrophilic radial sheaths with smaller outer diameters and tapered tips can reduce radial spasm and occlusion risk relative to conventional designs . Terumo's Glidesheath Slender preserves the functional inner lumen while reducing outer diameter by one French size, addressing the constrained diameter of radial arteries .

The design requirements change materially in specialty procedures. Gore's DRYSEAL Flex is offered in 10Fr to 26Fr sizes for endovascular aortic repair and uses a pressurized hemostasis valve to support device exchanges while maintaining access-site control . Abbott's Agilis NxT Dual-Reach received FDA clearance in June 2024 for transseptal access in electrophysiology procedures , while Cook's Volante provides deflection for complex intracardiac and peripheral access . These products compete on technical compatibility and workflow consequences, rather than only on unit price.

Favorable reimbursement policies in developed economies

Medicare coverage policies and outpatient payment rules support procedure volumes for cardiac catheterization and coronary angiography in the U.S. . CMS updated hospital outpatient and ASC payment policies for calendar year 2025, maintaining a reimbursement environment that supports catheter-based procedures in both settings . The migration of PCI into ASCs is commercially significant: cardiology-focused ASCs with active PCI programs increased from 55 in 2018 to 221 in 2023 .

Japan and China also reimburse catheter-based cardiovascular procedures through national insurance arrangements at hospitals . Reimbursement does not eliminate procurement pressure, but it supports the procedure volumes that create sheath demand. In outpatient settings, the value proposition increasingly depends on whether a product reduces preparation time, exchanges, or access-site complications within a fixed procedure payment.

Growing adoption of minimally invasive procedures

Transcatheter interventions continue to replace or supplement open surgical approaches in structural heart care. U.S. transcatheter aortic valve intervention volume grew at a 12.8% CAGR from 2015 to 2024, while surgical valve procedures declined . Larger-bore delivery systems used in TAVI and other structural procedures raise the revenue contribution per case because the access device must combine trackability, wall strength, and sustained hemostasis.

Radial access is also reshaping product specifications in coronary care. A 2024 registry from Kerala reported that transradial access accounted for 71% of PCI procedures, compared with 28% for femoral access . This institutional transition favors thin-wall, hydrophilic products in 5Fr–6Fr configurations. Meanwhile, percutaneous approaches in urology, gynecology, interventional radiology, and hepatobiliary care broaden the addressable procedure base beyond cardiovascular interventions.

Key Restraints

Key Restraints Impact Table

Stringent regulatory requirements for product approval

Regulatory requirements create a durable entry barrier, particularly for manufacturers seeking to enter multiple advanced markets with one platform. U.S. catheter introducers require 510(k) clearance under 21 CFR 870.1340 . Product changes can require evidence on biocompatibility, dimensional integrity, coating performance, and valve function. The process is less burdensome than premarket approval, but it still creates timing and validation costs that are particularly material for steerable, coated, and large-bore systems.

The EU Medical Device Regulation adds further compliance intensity. Regulation (EU) 2017/745 requires conformity assessment, clinical evaluation, and post-market surveillance obligations for relevant device classes . The commercial effect is not limited to an upfront approval delay: manufacturers need clinical, quality, and post-market systems capable of maintaining products across their lifecycle. This favors suppliers that can sustain regulatory documentation across broad portfolios.

Japan's PMDA processes and China's Class III device framework further complicate international launches. For imported products, these requirements can lengthen approval cycles and raise localization costs. Domestic suppliers in China consequently benefit from proximity to local documentation, distribution, and procurement systems, even when multinational manufacturers retain a clinical-performance advantage in specialty categories.

High costs of advanced introducer sheaths

Premium designs carry costs that are difficult to absorb under bundled-payment and diagnosis-related reimbursement models. Large-bore hemostatic systems, steerable sheaths, and hydrophilic thin-wall devices incorporate more complex materials, coatings, valves, and manufacturing controls than standard femoral or radial products. Hospital value-analysis committees and group purchasing organizations consequently compare clinical gains against procedure-level supply cost.

Cost pressure is most acute where procedure reimbursement is low relative to imported-device pricing. The World Stroke Organization reports that only 3% of countries provide the full spectrum of acute stroke reperfusion therapy . In those settings, thrombectomy infrastructure, trained operators, and reimbursement must develop together before high-value neurovascular sheath demand can scale. Epidemiological need alone cannot convert into market revenue when the access procedure remains economically inaccessible.

The competitive inflection lies in converting technical differentiation into a measurable procedure benefit. A product that reduces exchanges, stabilizes access during a radial procedure, or maintains hemostasis during a large-bore intervention can defend a premium only when the benefit is meaningful to a cath-lab workflow or complication-risk profile. Suppliers that cannot demonstrate that connection are exposed to price substitution even if their devices meet baseline regulatory and clinical requirements.

Catheter Introducer Sheaths Market Segment Analysis

By Product

Integrated introducer sheaths

Integrated introducer sheaths are projected to exceed USD 1.5 billion by 2035, growing at approximately 7%. Their single-unit construction reduces assembly steps and supports standardized setup in high-throughput catheterization laboratories. The segment ranges from routine radial products to high-complexity systems with hydrophilic coatings, side ports, and advanced valve designs.

Terumo's RADIFOCUS and Glidesheath platforms, Cordis's RAIN Sheath, and Gore's DRYSEAL Flex illustrate the dispersion within the segment. Cordis positions RAIN around hydrophilic coating, kink recovery, and a hexacuspid valve for radial access ^{[5]Cordis, RAIN Sheath Transradial Hydrophilic Thin-Walled Introducer, cordis.com}, while DRYSEAL addresses the substantially different demands of large-bore endovascular repair ^{[6]Gore Medical, GORE DRYSEAL Flex Introducer Sheath, goremedical.com}. Integrated sheaths therefore span both the market's most price-competitive category and its technically differentiated specialty products.

Separable introducer sheaths

Separable introducer sheaths were valued at USD 527.3 million in 2025 and are projected to approach USD 1.0 billion by 2035. Peel-away configurations are used in applications where the sheath must be removed after lead or catheter placement, including cardiac rhythm-device implantation and selected vascular-access procedures.

Merit Medical completed the acquisition of Cook Medical's Lead Management portfolio in November 2024, adding Peel-Away Introducer Sheath Sets, Curved Peel-Away sets, and Evolution RL dilator-sheath products to its offering . The transaction strengthens Merit's position in lead-management access and shifts established separable product lines into a supplier with a broader vascular-access sales infrastructure.

By Application

Cardiovascular

Cardiovascular applications are projected to reach approximately USD 1.3 billion by 2035. Demand covers coronary angiography, PCI, electrophysiology, TAVI, peripheral intervention, and structural-heart repair. The most important mix shift is toward procedures requiring larger, more specialized access systems, including valve interventions and electrophysiology procedures that depend on steerable transseptal access.

European procedural intensity provides a useful indication of the installed demand base. The ESC Atlas recorded 4,652.2 diagnostic catheterizations and 2,143.3 PCIs per million people across reporting European countries in 2024 . High procedure rates support stable baseline volume, while structural-heart expansion drives the premium end of the product mix.

Neurovascular

The neurovascular segment is projected to rise from USD 265.4 million in 2025 to USD 523 million by 2035 at a 6.8% CAGR. Mechanical thrombectomy is the principal demand driver because it requires long access sheaths capable of supporting balloon-guide catheters and neurovascular devices. The Thinline Introducer Sheath received FDA clearance in September 2023 for neurovascular use and is designed to maintain compatibility with large-bore balloon-guide catheters while reducing the closure size requirement .

Neurovascular growth remains infrastructure-dependent. A stroke center must combine imaging, trained interventionists, emergency coordination, and reimbursement before a thrombectomy program can generate recurring sheath consumption. The segment's forecast therefore reflects both procedure growth in established centers and the slower buildout of new stroke-capable networks.

Urological

Urological applications are projected to increase from USD 207 million in 2025 to USD 396.9 million by 2035. Introducer sheaths support ureteral access, nephrostomy, nephroscopy, and other percutaneous procedures. Product requirements typically favor smaller, shorter configurations than cardiovascular systems, with demand shaped by age-related renal and urinary disease and the use of minimally invasive access routes.

Gynecological

The gynecological segment is projected to grow from USD 100.6 million in 2025 to USD 184.1 million by 2035. Uterine fibroid embolization and other image-guided procedures use introducer sheaths as the vascular entry route for selective catheterization. The segment benefits from interest in uterus-conserving and minimally invasive alternatives, but its lower procedural intensity limits its contribution relative to cardiovascular and neurovascular applications.

Other applications

Other applications are expected to grow from USD 80.6 million in 2025 to USD 140.7 million by 2035. They include interventional radiology, oncological catheter placement, biliary and hepatic access, and transjugular intrahepatic portosystemic shunt procedures. Argon Medical launched the Intara Introducer Sheath in September 2024 for transjugular liver biopsy, TIPS, and portal-vein access applications . Such launches demonstrate that non-cardiovascular specialties can support targeted sheath innovation where access geometry and fluoroscopic visibility are procedure-critical.

By End Use

Hospitals

Hospitals held 62.3% of market revenue in 2025 because complex cardiovascular, structural-heart, and neurovascular procedures remain concentrated in tertiary facilities with dedicated cath labs, interventional-radiology suites, and stroke programs. Purchasing is commonly shaped by health-system standardization and GPO contracts. Broad portfolio coverage can be as important as a single product attribute because hospitals frequently rationalize suppliers across multiple access categories.

Ambulatory surgical centers

ASCs are projected to rise from USD 291.2 million in 2025 to USD 598 million by 2035, a 7.3% CAGR. The U.S. had 6,308 Medicare-certified ASCs in 2023, a 2.5% net increase from 2022 . As suitable diagnostic and interventional cardiology cases move out of hospital outpatient departments, ASC customers are likely to prioritize products that simplify setup, reduce turnover time, and support predictable access management under fixed payment structures.

Other end users

Specialty catheterization clinics, outpatient interventional-radiology facilities, and independent vascular-access centers form a smaller but expanding end-user group. Their purchasing behavior resembles the ASC model more closely than the large-hospital model: procedure efficiency and product availability can outweigh the centralized contracting advantages available to major health systems.

Neurovascular access represents the clearest long-term inflection. Disease incidence creates a substantial potential market, yet procedure demand emerges only after a health system establishes a complete thrombectomy pathway. Manufacturers seeking growth in this segment need more than a differentiated sheath: they need distribution, clinical training, and market-development capabilities that align with the formation of stroke-care networks. That dependence explains why neurovascular growth can remain attractive while still trailing the epidemiological expansion of stroke.

Catheter Introducer Sheaths Market Regional Analysis

North America

North America accounted for 32.8% of global market revenue in 2025. The region combines high procedure volumes, reimbursement support, established interventional infrastructure, and an expanding ASC channel. Its market is mature in standard coronary access, but structural heart, electrophysiology, venous intervention, and outpatient migration continue to support demand for specialty and workflow-oriented products.

United States

The U.S. market increased from USD 319.3 million in 2022 to USD 345.3 million in 2023, USD 372.6 million in 2024, and USD 397.5 million in 2025. It is projected to grow at a 4.6% CAGR from 2026 to 2035. The slower growth rate relative to the global market reflects mature radial-access adoption and price pressure on standard products. However, CMS outpatient and ASC payment policy continues to support catheter-based care outside inpatient settings ^{[7]Centers for Medicare & Medicaid Services, CY 2025 Medicare Hospital Outpatient Prospective Payment System and ASC Payment System Final Rule, cms.gov}, while structural-heart and electrophysiology procedures sustain demand for premium access systems.

Canada

Canada represents a smaller, stable market supported by provincial coverage of medically necessary cardiac procedures. Public procurement and budget discipline constrain broad premium adoption, although aging demographics and established cardiac-care capacity support consistent baseline procedure demand.

Europe

Europe was valued at USD 400.1 million in 2025. High procedural density, established public hospital systems, and strong structural-heart adoption support market value. Spain's 2024 catheterization registry reported growth in diagnostic procedures and ongoing expansion in structural interventions ^{[8]Revista Española de Cardiología, Spanish Cardiac Catheterization and Coronary Intervention Registry: 34th Official Report, pubmed.ncbi.nlm.nih.gov}. Germany, the UK, and France remain core demand centers, while Spain, Italy, and the Netherlands support mature secondary markets.

EU MDR requirements create a distinct regional competitive dynamic. Manufacturers that can sustain clinical evaluation and post-market obligations may gain share as smaller firms face a higher compliance burden . The regulatory effect is therefore likely to favor established suppliers, even though public procurement continues to exert unit-price pressure.

Asia Pacific

Asia Pacific is projected to grow at a 9.1% CAGR from 2026 to 2035. The region combines rising cardiovascular burden with the expansion of catheterization capacity and public insurance access. Its growth path is less dependent on replacing existing products than on creating new procedure capacity, especially outside major metropolitan centers.

China

China is the region's largest market. Its cardiovascular disease burden, hospital modernization initiatives, and expansion of catheterization capability in lower-tier cities support demand growth. Domestic manufacturers such as Lepu Medical benefit from local manufacturing and distribution advantages, while China's Class III regulatory framework can make market entry more demanding for imported devices.

Japan

Japan has the region's most mature interventional cardiology market and approximately 137 TAVR centers . Its aging population supports demand for cardiovascular and structural-heart interventions, while PMDA review expectations favor suppliers with mature clinical and regulatory documentation.

India

India presents a substantial long-term opportunity because ischemic heart disease and stroke account for more than 80% of cardiovascular deaths . Broader insurance coverage and additional catheterization capacity can translate this disease burden into procedures, but the pace of growth remains sensitive to affordability, specialist availability, and the operating economics of both public and private hospitals.

Australia and South Korea

Australia's cardiovascular disease burden includes approximately 1.3 million affected adults, and heart failure affected about 144,000 people in 2022 . Its structured regulatory environment and advanced procedure base support steady demand. South Korea's adoption of advanced PCI guidance and catheter-based interventions supports demand for access systems compatible with imaging and therapeutic devices.

Latin America

Latin America was valued at USD 97 million in 2025. Brazil leads regional demand through its large healthcare market and a combination of public Sistema Único de Saúde coverage and private hospital capacity. Mexico and Argentina provide secondary opportunities, particularly in metropolitan private-hospital networks. Currency volatility, import costs, and constrained public financing remain obstacles to the adoption of advanced imported sheath platforms.

Middle East and Africa

The Middle East and Africa market was valued at USD 43.3 million in 2025. Saudi Arabia and the UAE represent the principal premium markets because capital investment in referral hospitals and cardiovascular capacity supports complex procedures. South Africa remains the most developed sub-Saharan market through its private hospital sector. Elsewhere in the region, financing constraints restrict adoption of advanced large-bore and steerable systems.

Asia Pacific provides the largest incremental growth opportunity, but the 9.1% forecast depends on converting disease burden into functioning intervention pathways. China can generate scale but remains commercially complex for imported products; Japan supports high-value specialty demand but has slower demographic and procedure-growth dynamics; India offers the greatest volume potential but is most exposed to affordability and infrastructure constraints. Regional strategy therefore requires differentiated product, pricing, and regulatory approaches rather than a single emerging-market playbook.

Catheter Introducer Sheaths Market Share & Competitive Landscape

Abbott, BD, Medtronic, Stryker, and Terumo collectively hold approximately 42% of global market revenue. Competition is moderate rather than dominated by a single supplier because access requirements differ substantially across radial coronary intervention, electrophysiology, structural heart, neurovascular intervention, and interventional radiology.

Terumo, Cordis, and Merit Medical compete strongly in radial access. Abbott, Cook Medical, and Gore occupy more specialized positions in steerable and large-bore applications. BD and Medtronic benefit from hospital-system access and portfolio breadth. Integer participates primarily as an OEM and component manufacturing partner, while Lepu Medical has a strong China-focused position. Product complexity, clinical evidence, distribution coverage, and account-level procedural integration shape competition more than a single category-wide technology standard.

Abbott

Abbott's introducer sheath portfolio is anchored by the Agilis NxT steerable platform for transseptal electrophysiology access. The Dual-Reach configuration received FDA clearance in June 2024 ^{[9]U.S. Food and Drug Administration, Agilis NxT Steerable Introducer Dual-Reach, K241370, accessdata.fda.gov}. Abbott's strategic advantage is its ability to align sheath selection with a broader electrophysiology catheter and ablation ecosystem, increasing the relevance of procedural compatibility in high-volume EP accounts.

B Braun

B Braun provides vascular access products across cardiovascular and interventional-radiology applications. Its European distribution presence and hospital relationships support access to acute-care accounts, with competitive emphasis on supply continuity and portfolio breadth.

BD

BD's access portfolio includes the Introsyte range, MicroEZ Microintroducer Kit, and Halo One Thin-Walled Guiding Sheath. The company's broad hospital presence creates procurement advantages where customers seek consolidated access-device purchasing across peripheral, central, and interventional categories.

CONMED

CONMED participates primarily through its broader surgical-access portfolio. Its exposure to catheter introducer sheaths is narrower than that of cardiovascular-focused suppliers, but its surgical-suite relationships provide relevance in selected access applications.

Cook Medical

Cook Medical retains a position in specialty vascular access through products such as the Volante Steerable Guiding Sheath . Its divestiture of the Lead Management portfolio to Merit Medical in 2024 narrowed Cook's involvement in separable sheath products while maintaining its focus on complex cardiovascular and peripheral access.

Cordis

Cordis competes in transradial access through the RAIN Sheath, which incorporates a full-length hydrophilic coating, kink-recovery properties, and a hexacuspid hemostasis valve . The company operates in a high-volume but competitively intense market segment where clinical usability and distributor reach are central differentiators.

Integer Holdings

Integer Holdings is primarily an OEM and precision-manufacturing participant. It supplies components, assemblies, and finished device kits for medical-device partners, including products that require polymer extrusion, hemostasis-valve assembly, and catheter-system manufacturing capabilities.

Lepu Medical

Lepu Medical serves China's cardiovascular device market with products spanning coronary, electrophysiology, and interventional access applications. Local manufacturing, distribution, and familiarity with domestic approval and procurement processes position the company strongly in Chinese hospital markets.

Medtronic

Medtronic participates across electrophysiology, structural heart, and peripheral vascular access through products integrated with its broader cardiovascular ecosystem. The company's electrophysiology and structural-heart presence supports a system-level approach in which access-device selection can be linked to catheter, mapping, and treatment-platform choices.

Merit Medical

Merit Medical strengthened its position through the launch of the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology in August 2025 and the acquisition of Cook's Lead Management portfolio in November 2024 , . The combined portfolio expands Merit's participation across radial, peripheral, and separable access applications.

Stryker

Stryker expanded its venous-intervention position through the February 2025 acquisition of Inari Medical. Inari, now part of Stryker, launched the InThrill Thrombectomy System in July 2025, including a dedicated sheath for arteriovenous access and small-vessel thrombus treatment . The transaction broadens Stryker's relevance in catheter-based venous therapy.

Terumo

Terumo maintains a broad radial-access portfolio that includes RADIFOCUS introducers and Glidesheath Slender . Its radial-to-peripheral strategy extends the company's relationship with accounts that have standardized on Terumo access products for coronary procedures. The December 2024 U.S. launch of the R2P NaviCross peripheral support catheter broadened that ecosystem for radial peripheral interventions .

GORE

Gore's DRYSEAL Flex Introducer Sheath addresses large-bore endovascular repair with sizes from 10Fr to 26Fr and a pressurized hemostasis valve . Its application-specific engineering gives Gore a differentiated position in endovascular aortic repair and other procedures requiring sustained hemostasis during large-device exchanges.

Recent Industry Developments

• July 2025 - Stryker launches the InThrill Thrombectomy System: Inari Medical, now part of Stryker, launched the 8Fr over-the-wire InThrill system for arteriovenous access and small-vessel thrombus treatment, including a dedicated sheath .

• August 2025 - Merit Medical launches Prelude Wave with SnapFix Technology: Merit Medical introduced the Prelude Wave Hydrophilic Sheath Introducer with an integrated retention mechanism designed to reduce sheath migration during radial procedures .

• February 2025 - Stryker completes its acquisition of Inari Medical: Stryker completed the acquisition of Inari Medical on February 19, 2025, expanding its catheter-based venous-disease portfolio .

• April 2025 - Asahi Intecc USA partners with Medikit: Asahi Intecc USA announced U.S. distribution of Medikit's Super Sheath Introducer Sheath in standard, radiopaque, and XL configurations from 4Fr to 14Fr.